DGRh-S2e-Leitlinie

1.

Abid N, Bin Kahlid A (2009) Adult onset Stills disease in a tertiary care hospital of Pakistan. J Pak Med Assoc 59;7:464–467

2.

Aeberli D, Oertle S, Mauron H et al (2002) Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 132:414–422

3.

Aggarwal R, Ringold S, Khanna D et al (2015) Distinctions between diagnostic and classification criteria? Arthritis Care Res 67:891–897. https://doi.org/10.1002/acr.22583CrossRef

4.

Ahn SS, Yoo B‑W, Jung SM et al (2017) Application of the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome in patients with adult-onset still disease. J Rheumatol 44:996–1003. https://doi.org/10.3899/jrheum.161286CrossRef

5.

Aikawa NE, de Medeiros Ribeiro AC, Saad CGS et al (2011) Is anti-TNF switching in refractory Still’s disease safe and effective? Clin Rheumatol 30:1129–1134. https://doi.org/10.1007/s10067-011-1735-0CrossRef

6.

Akritidis N, Papadopoulos A, Pappas G (2006) Long-term follow-up of patients with adult-onset Still’s disease. Scand J Rheumatol 35:395–397. https://doi.org/10.1080/03009740600709816CrossRef

7.

Al-Arfaj AS, Al-Saleh S (2001) Adult-onset still’s disease in Saudi Arabia. Clin Rheumatol 20:197–200CrossRef

8.

Al-Temimi FA, George P (2006) adult onset still’s disease in oman. Sultan Qaboos Univ Med J 6:41–45

9.

An Y‑S, Suh C‑H, Jung J‑Y et al (2017) The role of 18F-fluorodeoxyglucose positron emission tomography in the assessment of disease activity of adult-onset Still’s disease. Korean J Intern Med 32:1082–1089. https://doi.org/10.3904/kjim.2015.322CrossRef

10.

Andres E (2001) Liver biopsy is not useful in the diagnosis of adult Still’s disease. Qjm 94:568–569. https://doi.org/10.1093/qjmed/94.10.568CrossRef

11.

Andres E, Ruellan A, Pflumio F et al (2002) Sensitivity of the criteria used to diagnose adult still’s disease in internal medicine practice. A study of 17 cases. Eur J Intern Med 13:136–138CrossRef

12.

Appenzeller S, Castro GRW, Costallat LTL, Samara AM, Bértolo MB (2005) Adult-Onset Still Disease in Southeast Brazil. J Clin Rheumatol 11(2):76–80CrossRef

13.

Asano T, Furukawa H, Sato S et al (2017) Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still’s disease. Arthritis Res Ther 19:199. https://doi.org/10.1186/s13075-017-1406-xCrossRef

14.

Asanuma YF, Mimura T, Tsuboi H et al (2015) Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol 25:393–400. https://doi.org/10.3109/14397595.2014.974881CrossRef

15.

Aydintug AO, D’Cruz D, Cervera R et al (1992) Low dose methotrexate treatment in adult Still’s disease. J Rheumatol 19:431–435

16.

Bae C‑B, Jung J‑Y, Kim H‑A, Suh C‑H (2015) Reactive Hemophagocytic syndrome in adult-onset still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine 94:e451. https://doi.org/10.1097/MD.0000000000000451CrossRef

17.

Bae C‑B, Suh C‑H, An J‑M et al (2014) Serum S100A12 May be a useful biomarker of disease activity in adult-onset still’s disease. J Rheumatol 41:2403–2408. https://doi.org/10.3899/jrheum.140651CrossRef

18.

Bambery P, Thomas RJ, Malhotra HS, Kaur U, Bhusnurmath SR, Deodhar SD (1992) Adult onset Still’s disease: clinical experience with 18 patients over 15 years in northern India. Ann Rheum Dis 51:529–532CrossRef

19.

Balci MA, Pamuk ÖN, Pamuk GE et al (2015) Epidemiology and outcome of adult-onset Still’s disease in Northwestern Thrace region in Turkey. Clin Exp Rheumatol 33:818–823

20.

Bannai E, Yamashita H, Kaneko S et al (2016) Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol 26:297–301CrossRef

21.

Baxevanos G, Tzimas T, Pappas G Akritidis N (2012) A series of 22 patients with adult-onset Still’s disease presenting with fever of unknown origin. A difficult diagnosis? Clin Rheumatol 31:49–53

22.

Becker H, Gaubitz M, Domschke W, Willeke P (2009) Potential role of macrophage migration inhibitory factor in adult-onset Still’s disease. Scand J Rheumatol 38:69–71CrossRef

23.

Behrens EM, Beukelman T, Gallo L et al (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 35:343–348

24.

Bilgin E, Hayran M, Erden A et al (2019) Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study. Clin Rheumatol 38:1699–1706. https://doi.org/10.1007/s10067-019-04455-yCrossRef

25.

Bindoli S, Galozzi P, Magnani F et al (2020) (18)F-Fluorodeoxyglucose positron emission tomography and computed tomography with magnetic resonance for diagnosing adult-onset still’s disease. Front Med 7:544412CrossRef

26.

Blank N, Hegenbart U, Lohse P et al (2015) Risk factors for AA amyloidosis in Germany. Amyloid Int J Exp Clin Investig 22:1–7. https://doi.org/10.3109/13506129.2014.980942CrossRef

27.

Bodard Q, Langlois V, Guilpain P et al (2021) Cardiac involvement in adult-onset Still’s disease: manifestations, treatments and outcomes in a retrospective study of 28 patients. J Autoimmun 116:102541CrossRef

28.

Borciuch C, Fauvernier M, Gerfaud-Valentin M et al (2021) Still’s disease mortality trends in France, 1979–2016: a multiple-cause-of-death study. J Clin Med 10:4544. https://doi.org/10.3390/jcm10194544CrossRef

29.

DGRh, Buttgereit F, Brabant T et al (2018) S3 guidelines on treatment of polymyalgia rheumatica : evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol 77:429–441. https://doi.org/10.1007/s00393-018-0476-8CrossRef

30.

Cabane J, Michon A, Ziza JM et al (1990) Comparison of long term evolution of adult onset and juvenile onset Still’s disease, both followed up for more than 10 years. Ann Rheum Dis 49:283–285. https://doi.org/10.1136/ard.49.5.283CrossRef

31.

Cagatay Y, Gul A, Cagatay A et al (2009) Adult-onset still’s disease. Int J Clin Pract 63:1050–1055. https://doi.org/10.1111/j.1742-1241.2007.01393.xCrossRef

32.

Campochiaro C, Farina N, Tomelleri A et al (2021) Drug retention rates of biological agents in adult onset Still’s disease. Semin Arthritis Rheum 51:1–6. https://doi.org/10.1016/j.semarthrit.2020.09.014CrossRef

33.

Cavagna L, Caporali R, Epis O et al (2001) Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol 19:329–332

34.

Cavalli G, Franchini S, Aiello P et al (2015) Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol 44:309–314CrossRef

35.

Cavalli G, Franchini S, Berti A et al (2013) Efficacy and safety of biologic agents in adult-onset still’s disease: a long-term follow-up of 19 patients at a single referral center. Abstr. 2028 Am. Coll. Rheumatol. Annu. Meet.

36.

Cavalli G, Tomelleri A, De Luca G et al (2019) Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther 21:54. https://doi.org/10.1186/s13075-019-1843-9CrossRef

37.

Chen DY (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 63:1300–1306. https://doi.org/10.1136/ard.2003.013680CrossRef

38.

Chen D‑Y, Chen Y‑M, Chen H‑H et al (2009) Functional association of interleukin 18 gene −607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset still’s disease. J Rheumatol 36:2284–2289. https://doi.org/10.3899/jrheum.090316CrossRef

39.

Chen D‑Y, Chen Y‑M, Chen H‑H et al (2010) The associations of circulating CD4 ⁺ CD25 ^high regulatory T cells and TGF‑β with disease activity and clinical course in patients with adult-onset Still’s disease. Connect Tissue Res 51:370–377. https://doi.org/10.3109/03008200903461462CrossRef

40.

Chen D‑Y, Chen Y‑M, Ho W‑L et al (2009) Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 68:1074–1075. https://doi.org/10.1136/ard.2008.098335CrossRef

41.

Chen D‑Y, Chen Y‑M, Lan J‑L et al (2010) Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Baillieres Clin Rheumatol 49:2305–2312. https://doi.org/10.1093/rheumatology/keq284CrossRef

42.

Chen D‑Y, Chen Y‑M, Lin C‑C et al (2015) The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease. BMC Musculoskelet Disord 16:111. https://doi.org/10.1186/s12891-015-0569-3CrossRef

43.

Chen D‑Y, Chuang H‑C, Lan J‑L et al (2012) Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still’s disease and may act as an activity marker. BMC Med 10:84. https://doi.org/10.1186/1741-7015-10-84CrossRef

44.

Chen D‑Y, Hsieh T‑Y, Hsieh C‑W et al (2007) Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still’s disease. Arthritis Rheum 57:1530–1538. https://doi.org/10.1002/art.23088CrossRef

45.

Chen D‑Y, Lan J‑L, Lin F‑J, Hsieh T‑Y (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 31:2189–2198

46.

Chen D‑Y, Lan J‑L, Lin F‑J, Hsieh T‑Y (2005) Association of intercellular adhesion molecule‑1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum 53:320–327. https://doi.org/10.1002/art.21164CrossRef

47.

Chen D‑Y, Lan J‑L, Lin F‑J, Hsieh T‑Y (2007) Elevated levels of soluble Fas (APO‑1, CD95), soluble Fas ligand, and matrix metalloproteinase‑3 in sera from patients with active untreated adult onset Still’s disease. Clin Rheumatol 26:393–400. https://doi.org/10.1007/s10067-006-0378-zCrossRef

48.

Chen D‑Y, Lin C‑C, Chen Y‑M et al (2013) Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still’s disease. Arthritis Res Ther 15:R39. https://doi.org/10.1186/ar4193CrossRef

49.

Chen YM, Hung WT, Chang WC et al (2020) Genetic association and expression correlation between colony-stimulating factor 1 gene encoding M‑CSF and adult-onset still’s disease. J Immunol Res. https://doi.org/10.1155/2020/8640719CrossRef

50.

Chi H, Liu D, Sun Y et al (2018) Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity. Arthritis Res Ther 20:54. https://doi.org/10.1186/s13075-018-1555-6CrossRef

51.

Chi H, Wang Z, Meng J et al (2020) A cohort study of liver involvement in patients with adult-onset still’s disease: prevalence, characteristics and impact on prognosis. Front Med 7:621005CrossRef

52.

Choi J‑H, Suh C‑H, Lee Y‑M et al (2003) Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol 30:2422–2427

53.

Cipriani P, Ruscitti P, Carubbi F et al (2014) Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol 33:49–55. https://doi.org/10.1007/s10067-013-2381-5CrossRef

54.

Colafrancesco S, Priori R, Aless et al (2012) IL-18 serum level in adult onset still’s disease: a marker of disease activity. Int J Inflam 2012:156890

55.

Colafrancesco S, Priori R, Alessandri C et al (2014) sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res 60:177–183. https://doi.org/10.1007/s12026-014-8563-7CrossRef

56.

Colafrancesco S, Priori R, Valesini G et al (2017) Response to Interleukin‑1 inhibitors in 140 Italian patients with adult-onset still’s disease: a multicentre retrospective observational study. Front Pharmacol 8:369CrossRef

57.

Colina M, Trotta F (2014) Clinical predictors in chronic articular adult-onset still’s disease: comment on the article by Ichida et al: letters. Arthritis Care Res 66:1127–1127. https://doi.org/10.1002/acr.22243CrossRef

58.

Colina M, Zucchini W, Ciancio G et al (2011) The evolution of adult-onset still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum 41:279–285. https://doi.org/10.1016/j.semarthrit.2010.12.006CrossRef

59.

Dall’Ara F, Frassi M, Tincani A, Airò P (2016) A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol 35:2117–2123CrossRef

60.

Debaugnies F, Mahadeb B, Ferster A et al (2016) Performances of the H‑score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am J Clin Pathol 145:862–870. https://doi.org/10.1093/ajcp/aqw076CrossRef

61.

Delplanque M, Pouchot J, Ducharme-Bénard S et al (2020) AA amyloidosis secondary to adult onset Still’s disease: About 19 cases. Semin Arthritis Rheum 50:156–165CrossRef

62.

Di Benedetto P, Cipriani P, Iacono D et al (2020) Ferritin and C‑reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS ONE 15:e235326CrossRef

63.

Efthimiou P (2006) Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis 65:564–572. https://doi.org/10.1136/ard.2005.042143CrossRef

64.

Elkayam O, Jiries N, Dranitzki Z et al (2014) Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol 41:244–247. https://doi.org/10.3899/jrheum.130881CrossRef

65.

Evensen KJ, Nossent HC (2006) Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol 35:48–51CrossRef

66.

Evensen KJ, Swaak TJG, Nossent JC (2007) Increased ferritin response in adult Still’s disease: specificity and relationship to outcome. Scand J Rheumatol 36:107–110. https://doi.org/10.1080/03009740600958504CrossRef

67.

Fardet L, Galicier L, Lambotte O et al (2014) Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome: score for reactive hemophagocytic syndrome. Arthritis Rheumatol 66:2613–2620. https://doi.org/10.1002/art.38690CrossRef

68.

Fautrel B (2005) Tumour necrosis factor blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis 64:262–266. https://doi.org/10.1136/ard.2004.024026CrossRef

69.

Fautrel B (2008) Adult-onset Still disease. Best Pract Res Clin Rheumatol 22:773–792CrossRef

70.

Fautrel B, Le Moël G, Saint-Marcoux B et al (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 28:322–329

71.

Feist E, Quartier P, Fautrel B et al (2018) Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 36:668–675

72.

Fiehn C, Holle J, Iking-Konert C et al (2018) S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs. Z Rheumatol 77:35–53. https://doi.org/10.1007/s00393-018-0481-yCrossRef

73.

Fitzgerald AA, LeClercq SA, Yan A et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 52:1794–1803. https://doi.org/10.1002/art.21061CrossRef

74.

Fortna RR, Gudjonsson JE, Seidel G et al (2010) Persistent pruritic papules and plaques: a characteristic histopathologic presentation seen in a subset of patients with adult-onset and juvenile Still’s disease. J Cutan Pathol 37:932–937. https://doi.org/10.1111/j.1600-0560.2010.01570.xCrossRef

75.

Franchini S, Dagna L, Salvo F et al (2010) Adult onset Still’s disease: clinical presentation in a large cohort of Italian patients. Clin Exp Rheumatol 28:41–48

76.

Franchini S, Dagna L, Salvo F et al (2010) Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum 62:2530–2535. https://doi.org/10.1002/art.27532CrossRef

77.

Fujii T, Akizuki M, Kameda H et al (1997) Methotrexate treatment in patients with adult onset Still’s disease—retrospective study of 13 Japanese cases. Ann Rheum Dis 56:144–148. https://doi.org/10.1136/ard.56.2.144CrossRef

78.

Fujita Y, Asano T, Matsumoto H et al (2020) Elevated serum levels of checkpoint molecules in patients with adult Still’s disease. Arthritis Res Ther 22:174. https://doi.org/10.1186/s13075-020-02263-3CrossRef

79.

Gabay C, Fautrel B, Rech J et al (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77:840–847

80.

Gerfaud-Valentin M, Maucort-Boulch D, Hot A et al (2014) Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine 93:91–99. https://doi.org/10.1097/MD.0000000000000021CrossRef

81.

Giampietro C, Ridene M, Fautrel B, Bourgeous P (2010) Long term treatment with Anakinra in patients with adult-onset still disease. Abstr. 902 Am. Coll. Rheumatol. Annu. Meet.

82.

Giampietro C, Ridene M, Lequerre T et al (2013) Anakinra in adult-onset still’s disease: long-term treatment in patients resistant to conventional therapy: long-term efficacy and safety of Anakinra in AOSD. Arthritis Care Res 65:822–826. https://doi.org/10.1002/acr.21901CrossRef

83.

Girard C, Rech J, Brown M et al (2016) Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Baillieres Clin Rheumatol 55:2237–2247. https://doi.org/10.1093/rheumatology/kew300CrossRef

84.

Guo Q, Zha X, Li C et al (2016) Serum calprotectin—a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol 35:73–79. https://doi.org/10.1007/s10067-015-3108-6CrossRef

85.

Gurion R, Lehman TJA, Moorthy LN (2012) Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflamm 2012:271569. https://doi.org/10.1155/2012/271569CrossRef

86.

Han JH, Suh C‑H, Jung J‑Y et al (2015) Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease. Arthritis Res Ther 17:260. https://doi.org/10.1186/s13075-015-0773-4CrossRef

87.

Han JH, Suh C‑H, Jung J‑Y et al (2017) Serum levels of Interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset still’s disease. J Rheumatol 44:740–747. https://doi.org/10.3899/jrheum.170020CrossRef

88.

Han JH, Suh C‑H, Jung J‑Y et al (2017) Elevated circulating levels of the interferon-γ–induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still’s disease. Sci Rep 7:46652. https://doi.org/10.1038/srep46652CrossRef

89.

Hassan SA, Choudhry AS, Jamal S et al (2020) Adult onset still’s disease: a retrospective, single-center study. Cureus. https://doi.org/10.7759/cureus.10008CrossRef

90.

Hinze CH, Holzinger D, Lainka E et al (2018) Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 16:7. https://doi.org/10.1186/s12969-018-0224-2CrossRef

91.

Hong D, Yang Z, Han S et al (2014) Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Devel Ther 8:2345–2357

92.

Hu Q, Gong W, Gu J et al (2019) Plasma microRNA profiles as a potential biomarker in differentiating adult-onset still’s disease from sepsis. Front Immunol 9:3099. https://doi.org/10.3389/fimmu.2018.03099CrossRef

93.

Hu Q, Wang M, Jia J et al (2020) Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China. Ann Rheum Dis 79:842–844. https://doi.org/10.1136/annrheumdis-2019-216699CrossRef

94.

Huscher D, Thiele K, Gromnica-Ihle E et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124. https://doi.org/10.1136/ard.2008.092163CrossRef

95.

Husni ME, Maier AL, Mease PJ et al (2002) Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 46:1171–1176. https://doi.org/10.1002/art.10231CrossRef

96.

Iliou C, Papagoras C, Tsifetaki N et al (2013) Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol 31:47–52

97.

Jeon YK (2004) Spectrum of lymph node pathology in adult onset Still’s disease; analysis of 12 patients with one follow up biopsy. J Clin Pathol 57:1052–1056. https://doi.org/10.1136/jcp.2004.018010CrossRef

98.

Jiang L, Wang Z, Dai X, Jin X (2011) Evaluation of clinical measures and different criteria for diagnosis of adult-onset Still’s disease in a Chinese population. J Rheumatol 38:741–746. https://doi.org/10.3899/jrheum.100766CrossRef

99.

Jiang L, Xiu Y, Gu T et al (2017) Imaging characteristics of adult onset Still’s disease demonstrated with 18F-FDG PET/CT. Mol Med Rep 16:3680–3686. https://doi.org/10.3892/mmr.2017.7022CrossRef

100.

Jung JH, Jun JB, Yoo DH et al (2000) High toxicity of sulfasalazine in adult-onset Still’s disease. Clin Exp Rheumatol 18:245–248

101.

Jung KH, Kim JJ, Lee JS et al (2014) Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease. Scand J Rheumatol 43:162–169CrossRef

102.

Jung S‑Y, Park Y‑B, Ha Y‑J et al (2010) Serum calprotectin as a marker for disease activity and severity in adult-onset still’s disease. J Rheumatol 37:1029–1034. https://doi.org/10.3899/jrheum.091120CrossRef

103.

Kallinich T, Blank N, Braun T et al (2019) Evidence-based treatment recommendations for familial Mediterranean fever : a joint statement by the society for pediatric and adolescent rheumatology and the German society for rheumatology. Z Rheumatol 78:91–101. https://doi.org/10.1007/s00393-018-0588-1CrossRef

104.

Kalyoncu U, Solmaz D, Emmungil H et al (2016) Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset still’s disease: data from a large multicenter cohort. J Autoimmun 69:59–63. https://doi.org/10.1016/j.jaut.2016.02.010CrossRef

105.

Kaneko Y, Kameda H, Ikeda K et al (2018) Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77:1720–1729. https://doi.org/10.1136/annrheumdis-2018-213920CrossRef

106.

Kawaguchi Y, Terajima H, Harigai M et al (2001) Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still’s disease. Arthritis Rheum 44:1716–1717. https://doi.org/10.1002/1529-0131(200107)44:7〈1716::AID-ART298〉3.0.CO;2‑ICrossRef

107.

Kawashima M, Yamamura M, Taniai M et al (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum 44:550–560. https://doi.org/10.1002/1529-0131(200103)44:3〈550::AID-ANR103〉3.0.CO;2‑5CrossRef

108.

Kedor C, Listing J, Zernicke J et al (2020) Canakinumab for treatment of adult-onset still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 79:1090–1097CrossRef

109.

Kiltz U, Alten R, Fleck M et al (2017) Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF. Z Rheumatol 76:118–124. https://doi.org/10.1007/s00393-016-0249-1CrossRef

110.

Kiltz U, Kiefer D, Braun J et al (2020) Prolonged treatment with tadekinig alfa in adult-onset still’s disease. Ann Rheum Dis 79:e10CrossRef

111.

Kim H‑A, An J‑M, Nam J‑Y et al (2012) Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol 39:1399–1406. https://doi.org/10.3899/jrheum.120079CrossRef

112.

Kim H‑A, Kwon JE, Yim H et al (2015) The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine 94:e787. https://doi.org/10.1097/MD.0000000000000787CrossRef

113.

Kim JJ, Kim J‑K, Shim S‑C et al (2013) MEFV gene mutations and their clinical significance in Korean patients with adult-onset Still’s disease. Clin Exp Rheumatol 31:60–63

114.

Kim J‑W, Jung J‑Y, Suh C‑H, Kim H‑A (2021) Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still’s disease. Clin Rheumatol 40:661–668. https://doi.org/10.1007/s10067-020-05266-2CrossRef

115.

Kim YJ, Koo BS, Kim Y‑G et al (2014) Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol 32:28–33

116.

Kirino Y, Kawaguchi Y, Tada Y et al (2018) Beneficial use of serum ferritin and heme oxygenase‑1 as biomarkers in adult-onset still’s disease: a multicenter retrospective study. Mod Rheumatol 28:858–864. https://doi.org/10.1080/14397595.2017.1422231CrossRef

117.

Kirino Y, Takeno M, Iwasaki M et al (2005) Increased serum HO‑1 in hemophagocytic syndrome and adult-onset Still’s disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther 7:R616–24CrossRef

118.

Kır S, Özgen M, Zontul S (2021) Adult-onset still’s disease and treatment results with tocilizumab. Int J Clin Pract. https://doi.org/10.1111/ijcp.13936CrossRef

119.

Koga T, Sumiyoshi R, Furukawa K et al (2020) Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still’s disease from sepsis. Arthritis Res Ther 22:108. https://doi.org/10.1186/s13075-020-02200-4CrossRef

120.

Koizumi R, Tsukada Y, Ideura H et al (2000) Treatment of adult Still’s disease with dexamethasone, an alternative to prednisolone. Scand J Rheumatol 29:396–398CrossRef

121.

Kokkinos A, Iliopoulos A, Greka P et al (2004) Successful treatment of refractory adult-onset Still?s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23:45–49. https://doi.org/10.1007/s10067-003-0775-5CrossRef

122.

Kokkinos A, Iliopoulos A, Greka P et al (2004) Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23:45–49CrossRef

123.

Komiya A, Matsui T, Nogi S et al (2012) Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol 41:156–158. https://doi.org/10.3109/03009742.2011.644325CrossRef

124.

Kong XD, Xu D, Zhang W et al (2010) Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol 29:1015–1019CrossRef

125.

Kontzias A, Efthimiou P (2008) Adult-onset Still’s disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs 68:319–337CrossRef

126.

Kötter I, Wacker A, Koch S et al (2007) Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37:189–197. https://doi.org/10.1016/j.semarthrit.2007.04.002CrossRef

127.

Kraetsch HG, Antoni C, Kalden JR, Manger B (1997) Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 60:iii55–iii57

128.

Kudela H, Drynda S, Lux A et al (2019) Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol 3:4CrossRef

129.

Kuroda T, Tanabe N, Harada T et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505. https://doi.org/10.1007/s10067-005-0079-zCrossRef

130.

Kwok JS‑S, Wong PC‑H, Luk MC, Chan MH‑M (2012) Use of glycosylated ferritin assay to aid the diagnosis of adult-onset Still’s disease: a local laboratory experience in Hong Kong. Rheumatol Int 32:2583–2584. https://doi.org/10.1007/s00296-011-2006-8CrossRef

131.

La Rosée P, Horne A, Hines M et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133:2465–2477. https://doi.org/10.1182/blood.2018894618CrossRef

132.

Lambotte O, Cacoub P, Costedoat N et al (2003) High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 30:1027–1028

133.

Larson AR, Laga AC, Granter SR (2015) The spectrum of histopathologic findings in cutaneous lesions in patients with still disease. Am J Clin Pathol 144:945–951. https://doi.org/10.1309/AJCPZE77UAPSMDCDCrossRef

134.

Laskari K, Tektonidou MG, Katsiari C et al (2021) Outcome of refractory to conventional and/or biologic treatment adult still’s disease following canakinumab treatment: countrywide data in 50 patients. Semin Arthritis Rheum 51:137–143. https://doi.org/10.1016/j.semarthrit.2020.10.011CrossRef

135.

Laskari K, Tzioufas AG, Moutsopoulos HM (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther 13:R91. https://doi.org/10.1186/ar3366CrossRef

136.

Lebrun D, Mestrallet S, Dehoux M et al (2018) Validation of the Fautrel classification criteria for adult-onset Still’s disease. Semin Arthritis Rheum 47:578–585. https://doi.org/10.1016/j.semarthrit.2017.07.005CrossRef

137.

Lee JY‑Y, Hsu C‑K, Liu M‑F, Chao S‑C (2012) Evanescent and persistent pruritic eruptions of adult-onset still disease: a clinical and pathologic study of 36 patients. Semin Arthritis Rheum 42:317–326. https://doi.org/10.1016/j.semarthrit.2012.05.003CrossRef

138.

Lee S‑W, Park Y‑B, Song J‑S, Lee S‑K (2009) The mid-range of the adjusted level of ferritin can predict the chronic course in patients with adult onset Still’s disease. J Rheumatol 36:156–162. https://doi.org/10.3899/jrheum.080537CrossRef

139.

Lenert A, Yao Q (2016) Macrophage activation syndrome complicating adult onset Still’s disease: A single center case series and comparison with literature. Semin Arthritis Rheum 45:711–716. https://doi.org/10.1016/j.semarthrit.2015.11.002CrossRef

140.

Lequerré T, Quartier P, Rosellini D et al (2008) Interleukin‑1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302–308CrossRef

141.

Li H, Abramova I, Chesoni S, Yao Q (2018) Molecular genetic analysis for periodic fever syndromes: a supplemental role for the diagnosis of adult-onset Still’s disease. Clin Rheumatol 37:2021–2026CrossRef

142.

Li T, Gu L, Wang X et al (2017) A pilot study on tocilizumab for treating refractory adult-onset still’s disease. Sci Rep 7:13477. https://doi.org/10.1038/s41598-017-13639-yCrossRef

143.

Lian F, Wang Y, Yang X et al (2012) Clinical features and hyperferritinemia diagnostic cutoff points for AOSD based on ROC curve: a Chinese experience. Rheumatol Int 32:189–192. https://doi.org/10.1007/s00296-010-1601-4CrossRef

144.

Lim E, Chng HH (1998) Adult-onset Still’s disease in an oriental population: manifestations, course and outcome in 16 patients. Ann Acad Med Singapore 27:11–15

145.

Lin SJ, Chao HC, Yan DC (2000) Different articular outcomes of Still’s disease in Chinese children and adults. Clin Rheumatol 19:127–130. https://doi.org/10.1007/s100670050030CrossRef

146.

Liu Z, Lv X, Tang G (2015) Clinical features and prognosis of adult-onset Still’s disease: 75 cases from China. Int J Clin Exp Med 8:16634–16639

147.

Luthi F, Zufferey P, Hofer MF, So AK (2002) “Adolescent-onset Still’s disease”: characteristics and outcome in comparison with adult-onset Still’s disease. Clin Exp Rheumatol 20:427–430

148.

Ma Y, Wu M, Zhang X et al (2018) Efficacy and safety of tocilizumab with inhibition of interleukin‑6 in adult-onset still’s disease: a meta-analysis. Mod Rheumatol 28:849–857. https://doi.org/10.1080/14397595.2017.1416924CrossRef

149.

Maeda-Aoyama N, Hamada-Ode K, Taniguchi Y et al (2020) Dyskeratotic cells in persistent pruritic skin lesions as a prognostic factor in adult-onset Still disease. Medicine 99:e19051CrossRef

150.

Magadur-Joly G, Billaud E, Barrier JH et al (1995) Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54:587–590CrossRef

151.

Mahfoudhi M, Shimi R, Turki S, Kheder A (2015) Epidemiology and outcome of articular complications in adult onset still’s disease. Pan Afr Med J. https://doi.org/10.11604/pamj.2015.22.77.6366CrossRef

152.

Maruyama A, Kokuzawa A, Yamauchi Y et al (2021) Clinical features of elderly-onset adult-onset still’s disease. Mod Rheumatol 31:862–868. https://doi.org/10.1080/14397595.2020.1829340CrossRef

153.

Matsui K, Tsuchida T, Hiroishi K et al (1999) High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still’s disease. Rheumatology 38:477–478. https://doi.org/10.1093/rheumatology/38.5.477CrossRef

154.

Mehrpoor G, Owlia MB, Soleimani H, Ayatollahi J (2008) Adult-onset Still’s disease: a report of 28 cases and review of the literature. Mod Rheumatol 18:480–485CrossRef

155.

Mert A, Ozaras R, Tabak F et al (2003) Fever of unknown origin: a review of 20 patients with Adult-onset Still’s disease. Clin Rheumatol 22:89–93. https://doi.org/10.1007/s10067-002-0680-3CrossRef

156.

Mimura T, Kondo Y, Ohta A et al (2018) Evidence-based clinical practice guideline for adult Still’s disease. Mod Rheumatol 28:736–757CrossRef

157.

Min JK, Cho CS, Kim HY, Oh EJ (2003) Bone marrow findings in patients with adult Still’s disease. Scand J Rheumatol 32:119–121CrossRef

158.

Minoia F, Bovis F, Davì S et al (2019) Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis 78:1357–1362. https://doi.org/10.1136/annrheumdis-2019-215211CrossRef

159.

Mitamura M, Tada Y, Koarada S et al (2009) Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol 19:57–63CrossRef

160.

Mock B, Hein G, Stein G (1997) Still-Syndrom des Erwachsenen. Med Klin 92:515–520. https://doi.org/10.1007/BF03044924CrossRef

161.

Mok CC, Lau CS, Wong RW (1998) Clinical characteristics, treatment, and outcome of adult onset Still’s disease in southern Chinese. J Rheumatol 25:2345–2351

162.

Moore C, Ormseth M, Fuchs H (2013) Causes and significance of markedly elevated serum Ferritin levels in an academic medical center. J Clin Rheumatol 19:324–328. https://doi.org/10.1097/RHU.0b013e31829ce01fCrossRef

163.

Motohashi R, Uchiyama K, Ikeuchi H et al (2018) Five patients who died during treatment for adult Still’s disease. Mod Rheumatol 28:381–382. https://doi.org/10.1080/14397595.2017.1351048CrossRef

164.

Nakamura H, Fujieda Y, Tarumi M et al (2020) Calcineurin inhibitors for adult-onset Still’s disease: a multicentre retrospective cohort study. Clin Exp Rheumatol 38(Suppl 127):11–16

165.

Nakamura H, Odani T, Shimizu Y et al (2016) Usefulness of tacrolimus for refractory adult-onset still’s disease: report of six cases. Mod Rheumatol 26:963–967. https://doi.org/10.3109/14397595.2014.933997CrossRef

166.

Narváez J, Mora-Limiñana M, Ros I et al (2019) Pulmonary arterial hypertension in adult-onset still’s disease: a case series and systematic review of the literature. Semin Arthritis Rheum 49:162–170. https://doi.org/10.1016/j.semarthrit.2018.11.007CrossRef

167.

Naumann L, Feist E, Natusch A et al (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis 69:466–467. https://doi.org/10.1136/ard.2009.108068CrossRef

168.

Néel A, Wahbi A, Tessoulin B et al (2018) Diagnostic and management of life-threatening adult-onset still disease: a French nationwide multicenter study and systematic literature review. Crit Care 22:88CrossRef

169.

Nirmala N, Brachat A, Feist E et al (2015) Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol 13:50. https://doi.org/10.1186/s12969-015-0047-3CrossRef

170.

Nishina N, Kaneko Y, Kameda H, Takeuchi T (2015) The effect of tocilizumab on preventing relapses in adult-onset still’s disease: a retrospective, single-center study. Mod Rheumatol 25:401–404. https://doi.org/10.3109/14397595.2014.973659CrossRef

171.

Nordström D, Knight A, Luukkainen R et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 39:2008–2011CrossRef

172.

Novak S, Anic F, Luke-Vrbanić TS (2012) Extremely high serum ferritin levels as a main diagnostic tool of adult-onset Still’s disease. Rheumatol Int 32:1091–1094CrossRef

173.

Okabe T, Shibata H, Shizukuishi K et al (2011) F‑18 FDG uptake patterns and disease activity of collagen vascular diseases-associated arthritis. Clin Nucl Med 36:350–354. https://doi.org/10.1097/RLU.0b013e318212c858CrossRef

174.

Oommen PT, Hinze C, Holzinger D et al (2020) Therapie der juvenilen idiopathischen Arthritis (JIA): Aktualisierung der interdisziplinären AWMF-S2k-Leitlinie „Therapie der juvenilen idiopathischen Arthritis“. Arthritis Rheuma 40:260–269. https://doi.org/10.1055/a-1161-5382CrossRef

175.

Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset still’s disease: multicenter retrospective open-label study of thirty-four patients: Tocilizumab in AOSD refractory to standard treatment. Arthritis Rheumatol 66:1659–1665. https://doi.org/10.1002/art.38398CrossRef

176.

Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al (2015) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66:1659–1665CrossRef

177.

Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L et al (2015) Efficacy of Anakinra in refractory adult-onset still’s disease: multicenter study of 41 patients and literature review. Medicine 94:e1554. https://doi.org/10.1097/MD.0000000000001554CrossRef

178.

Park H‑J, Ha Y‑J, Pyo J‑Y et al (2014) Delta neutrophil index as an early marker for differential diagnosis of adult-onset still’s disease and sepsis. Yonsei Med J 55:753. https://doi.org/10.3349/ymj.2014.55.3.753CrossRef

179.

Park H‑J, Song J, Park Y‑B et al (2018) Red blood cell distribution width is useful in discriminating adult onset Still’s disease and sepsis within 24 hours after hospitalization. Korean J Intern Med 33:1234–1240. https://doi.org/10.3904/kjim.2016.068CrossRef

180.

Pay S, Türkçapar N, Kalyoncu M et al (2006) A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 25:639–644CrossRef

181.

Petryna O, Cush JJ, Efthimiou P (2012) IL‑1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis 71:2056–2058. https://doi.org/10.1136/annrheumdis-2012-201409CrossRef

182.

Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392

183.

Pouchot J, Sampalis JS, Beaudet F et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine 70:118–136CrossRef

184.

Priori R, Barone F, Alessandri C et al (2011) Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Baillieres Clin Rheumatol 50:776–780. https://doi.org/10.1093/rheumatology/keq397CrossRef

185.

Priori R, Colafrancesco S, Alessandri C et al (2014) Interleukin 18: a Biomarker for differential diagnosis between adult-onset still’s disease and sepsis. J Rheumatol 41:1118–1123. https://doi.org/10.3899/jrheum.130575CrossRef

186.

Puéchal X, DeBandt M, Berthelot J‑M et al (2011) Tocilizumab in refractory adult still’s disease: refractory ASD and tocilizumab. Arthritis Care Res 63:155–159. https://doi.org/10.1002/acr.20319CrossRef

187.

Qiao J, Zhou S, Li S et al (2019) Histopathological diagnosis of persistent pruritic eruptions associated with adult-onset Still’s disease. Histopathology 74:759–765CrossRef

188.

Rech J, Ronneberger M, Englbrecht M et al (2011) Successful treatment of adult-onset Still’s disease refractory to TNF and IL‑1 blockade by IL‑6 receptor blockade. Ann Rheum Dis 70:390–392. https://doi.org/10.1136/ard.2010.129403CrossRef

189.

Reddy Munagala VV, Misra R, Agarwal V et al (2012) Adult onset Still’s disease: experience from a tertiary care rheumatology unit. Int J Rheum Dis 15:e136–e141. https://doi.org/10.1111/1756-185X.12012CrossRef

190.

Reihl Crnogaj M, Čubelić D, Babić A et al (2020) Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review. Rheumatol Int 40:1317–1325CrossRef

191.

Riera E, Olivé A, Narváez J et al (2011) Adult onset Still’s disease: review of 41 cases. Clin Exp Rheumatol 29:331–336

192.

Rossi-Semerano L, Fautrel B, Wendling D et al (2015) Tolerance and efficacy of off-label anti-interleukin‑1 treatments in France: a nationwide survey. Orphanet J Rare Dis 10:19CrossRef

193.

Ruscitti P, Berardicurti O, Iacono D et al (2020) Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther 22:151. https://doi.org/10.1186/s13075-020-02245-5CrossRef

194.

Ruscitti P, Cipriani P, Liakouli V et al (2019) Managing adult-onset still’s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine 98:e15123. https://doi.org/10.1097/MD.0000000000015123CrossRef

195.

Ruscitti P, Cipriani P, Liakouli V et al (2020) Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort. Rheumatol Int 40:107–113. https://doi.org/10.1007/s00296-019-04358-wCrossRef

196.

Ruscitti P, Cipriani P, Masedu F et al (2016) Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med 14:194. https://doi.org/10.1186/s12916-016-0738-8CrossRef

197.

Ruscitti P, Ursini F, Sota J et al (2020) The reduction of concomitant glucocorticoids dosage following treatment with IL‑1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies. Ther Adv Musculoskelet Dis 12:1759720x20933133CrossRef

198.

Saiki O, Uda H, Nishimoto N et al (2004) Adult still’s disease reflects a th2 rather than a th1 cytokine profile. Clin Immunol 112:120–125. https://doi.org/10.1016/j.clim.2004.03.023CrossRef

199.

Sakairi T, Hiromura K, Kaneko Y et al (2016) Histological findings in the spleen affected by adult-onset Still’s disease: a report of three cases. Clin Exp Rheumatol 34:566–567

200.

Sanchez Loria DM, Alvarez MMJ, Barceló HA et al (1996) Sjögren’s in adult Still’s disease? Clin Rheumatol 15:133–136CrossRef

201.

Saviola G, Benucci M, Abdi-Ali L et al (2010) Clarithromycin in adult-onset Still’s disease: a study of 6 cases. Rheumatol Int 30:555–560. https://doi.org/10.1007/s00296-009-1277-9CrossRef

202.

Schanberg L, Nigrovic P, Cooper A et al (2020) A randomized, double-blind, placebo-controlled study of anakinra in pediatric and adult patients with still’s disease. Arthritis Rheumatol 72:47–49

203.

Schiller D, Mittermayer H (1998) Hyperferritinemia as a marker of Still’s disease. Clin Infect Dis 26:534–535. https://doi.org/10.1086/517085CrossRef

204.

Segawa S, Kondo Y, Nakai Y et al (2018) Placenta specific 8 suppresses IL-18 production through regulation of autophagy and is associated with adult still disease. J Immunol 201:3534–3545. https://doi.org/10.4049/jimmunol.1800667CrossRef

205.

Sfriso P, Priori R, Valesini G et al (2016) Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 35:1683–1689. https://doi.org/10.1007/s10067-016-3308-8CrossRef

206.

Shimizu T, Kikuchi-Taura A, Tsuji S et al (2020) Up-regulation of CD64 expression on monocytes in patients with active adult-onset still disease: a possible biomarker of disease activity. J Clin Rheumatol

207.

Sighart R, Rech J, Hueber A et al (2018) Evidence for genetic overlap between adult onset Still’s disease and hereditary periodic fever syndromes. Rheumatol Int 38:111–120. https://doi.org/10.1007/s00296-017-3885-0CrossRef

208.

Singh NN, Ramji DP (2008) Protein kinase CK2, an important regulator of the inflammatory response? J Mol Med 86:887–897. https://doi.org/10.1007/s00109-008-0352-0CrossRef

209.

Singh YN, Adya CM, Kumar A, Malaviya AN (1992) Adult-onset Still’s disease in India. Br J Rheumatol 31:417–419. https://doi.org/10.1093/rheumatology/31.6.417CrossRef

210.

Sobieska M, Fassbender K, Aeschlimann A et al (1998) Still’s disease in children and adults: a distinct pattern of acute-phase proteins. Clin Rheumatol 17:258–260CrossRef

211.

Song ST, Kim JJ, Lee S et al (2016) Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol 34:S64–S71

212.

Sota J, Rigante D, Ruscitti P et al (2019) Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease. Front Pharmacol 10:918CrossRef

213.

Specker C, Schulze-Koops H, Ad-hoc-Kommission COVID-19 der DGRh, Vorstand der DGRh (2021) Vaccination against SARS-CoV‑2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients. Z Rheumatol 80:43–44. https://doi.org/10.1007/s00393-020-00955-4CrossRef

214.

Still GF (1941) On a form of chronic joint disease in children. Arch Dis Child 16:156–165. https://doi.org/10.1136/adc.16.87.156CrossRef

215.

Suematsu R, Ohta A, Matsuura E et al (2012) Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol 22:712–719. https://doi.org/10.3109/s10165-011-0569-6CrossRef

216.

Sun Y, Wang Z, Chi H et al (2019) Elevated serum levels of interleukin-10 in adult-onset Still’s disease are associated with disease activity. Clin Rheumatol 38:3205–3210. https://doi.org/10.1007/s10067-019-04642-xCrossRef

217.

Takakuwa Y, Hanaoka H, Kiyokawa T et al (2019) Adult-onset Still’s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse. Clin Exp Rheumatol 37(Suppl 121):23–27

218.

Takakuwa Y, Hanaoka H, Kiyokawa T et al (2019) Adult-onset Still’s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse. Clin Exp Rheumatol 37:23–27

219.

Tomaras S, Goetzke CC, Kallinich T, Feist E (2021) Adult-onset still’s disease: clinical aspects and therapeutic approach. J Clin Med 10:733. https://doi.org/10.3390/jcm10040733CrossRef

220.

Ugurlu S, Guzelant G, Yurttas B et al (2018) Canakinumab treatment in adult-onset still’s disease: case series. Arthritis Rheumatol 70:1450

221.

Uppal SS, Al-Mutairi M, Hayat S et al (2007) Ten years of clinical experience with adult onset Still’s disease: is the outcome improving? Clin Rheumatol 26:1055–1060. https://doi.org/10.1007/s10067-006-0440-xCrossRef

222.

Uppal SS, Pande IR, Kumar A et al (1995) Adult onset Still’s disease in northern India: comparison with juvenile onset Still’s disease. Br J Rheumatol 34:429–434. https://doi.org/10.1093/rheumatology/34.5.429CrossRef

223.

Vanderschueren S, Hermans F, De Munter P, Knockaert D (2012) Adult-onset Still’s disease: still a diagnosis of exclusion. A nested case-control study in patients with fever of unknown origin. Clin Exp Rheumatol 30:514–519

224.

Vercruysse F, Barnetche T, Lazaro E et al (2019) Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21:53. https://doi.org/10.1186/s13075-019-1838-6CrossRef

225.

Vercruysse F, Barnetche T, Lazaro E et al (2019) Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21:53CrossRef

226.

Vignes S, Le Moël G, Fautrel B et al (2000) Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still’s disease. Ann Rheum Dis 59:347–350. https://doi.org/10.1136/ard.59.5.347CrossRef

227.

Vitale A, Berlengiero V, Sota J et al (2020) Real-life data on the efficacy of canakinumab in patients with adult-onset still’s disease. Mediators Inflamm 2020:8054961CrossRef

228.

Vitale A, Cavalli G, Colafrancesco S et al (2019) Long-term retention rate of Anakinra in adult onset still’s disease and predictive factors for treatment response. Front Pharmacol 10:296CrossRef

229.

Vitale A, Cavalli G, Ruscitti P et al (2020) Comparison of early vs. Delayed Anakinra treatment in patients with adult onset still’s disease and effect on clinical and laboratory outcomes. Front Med 7:42CrossRef

230.

Vitale A, Insalaco A, Sfriso P et al (2016) A snapshot on the on-label and off-label use of the Interleukin‑1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. https://doi.org/10.3389/fphar.2016.00380CrossRef

231.

Wakai K, Ohta A, Tamakoshi A et al (1997) Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in. Jpn J Epidemiol 7:221–225. https://doi.org/10.2188/jea.7.221CrossRef

232.

Waljee AK, Rogers MAM, Lin P et al (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357:j1415. https://doi.org/10.1136/bmj.j1415CrossRef

233.

Wang C, Guo S, Wang L, Shen H (2019) Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: a STROBE-compliant article. Medicine 98:e16682. https://doi.org/10.1097/MD.0000000000016682CrossRef

234.

Wang F‑F, Huang X‑F, Shen N et al (2013) A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 15:R65. https://doi.org/10.1186/ar4239CrossRef

235.

Woerner A, von Scheven-Gête A, Cimaz R, Hofer M (2015) Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol 11:575–588. https://doi.org/10.1586/1744666X.2015.1032257CrossRef

236.

Yao T‑C, Huang Y‑W, Chang S‑M et al (2020) Association between oral corticosteroid bursts and severe adverse events : a nationwide population-based cohort study. Ann Intern Med 173:325–330. https://doi.org/10.7326/M20-0432CrossRef

237.

Lee Y‑YJ, Yang C‑C, Hsu M‑LM (2005) Histopathology of persistent papules and plaques in adult-onset Still’s disease. J Am Acad Dermatol 52:1003–1008. https://doi.org/10.1016/j.jaad.2005.02.032CrossRef

238.

Zeng T, Zou Y‑Q, Wu M‑F, Yang C‑D (2009) Clinical features and prognosis of adult-onset still’s disease: 61 cases from China. J Rheumatol 36:1026–1031. https://doi.org/10.3899/jrheum.080365CrossRef

239.

Zhang L, Yang X, Li T‑F et al (2020) Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease-associated macrophage activation syndrome. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217917CrossRef

240.

Zhang M, Wang Y, Li J, Zhou J (2020) Adult-onset Still’s disease presenting as fever of unknown origin: a single-center retrospective observational study from China. Ann Palliat Med 9:2786–2792. https://doi.org/10.21037/apm-20-268CrossRef

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

DGRh-S2e-Leitlinie

Diagnostik und Therapie des adulten Still-Syndroms (AOSD)

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Innere Medizin